Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multipronged R&D strategy GlaxoSmithKline, Medicago hit 75% efficacy against delta COVID strain, but omicron muddies waters 'Don't check yourself when you come to work': Being openly LGBTQ+ in a scientist-led industry Odyssey starts journey with $218M for 7 assets across cancer, inflammation with IFM, Scorpion founder at the helm J&J squares up to Big Pharma rivals with extra RSV vaccine data Metis Therapeutics emerges with $86M for 2022 clinic entry, push into gene therapy Apple Tree Partners breaks into UK with biotech Adendra Therapeutics launch, $53M series A raise Could Viagra prevent and treat Alzheimer's? Cleveland Clinic team shows its potential Merck's Hilleman Laboratories tees up $58M investment at new Singapore vaccine hub Providers still skeptical about wearable accuracy, integration abilities FDA spots 26 tests where omicron detection requires further confirmation Featured Story | By Nick Paul Taylor Are the foundations of Merck’s broad HIV development program crumbling? Having already paused combination work in response to a red flag, Merck has now temporarily stopped enrollment in phase 3 studies that are testing the backbone of its HIV strategy as a monotherapy. read more |
| |
|---|
|
Top Stories By Ben Adams GlaxoSmithKline and partner Medicago have seen some strong efficacy numbers against current dominating SARS-CoV-02 strain delta, but the emergence of omicron will likely upset these numbers. read more By Kyle LaHucik Biopharma leaders share their stories of coming out over the decades and what it means to have out members of the community in the top echelons of drug development. But being out shouldn't be a prerequisite for fostering safe, welcoming workplaces. read more By Kyle LaHucik After leading Scorpion Therapeutics through $270 million in financing rounds last year, Gary Glick is back with his fifth startup: Odyssey Therapeutics. Glick's latest odyssey launches with $218 million to bankroll seven assets in oncology and inflammation. read more By Nick Paul Taylor With GlaxoSmithKline, Pfizer and others in the running, Johnson & Johnson may need excellent data to capture the RSV vaccine market. The Big Pharma gave a further show of its credentials on Tuesday by sharing additional data from a study of thousands of seniors. read more By Kyle LaHucik Metis Therapeutics launched with $86 million to test its lead candidate in an early-2022 clinical trial and to bankroll the in-licensing of new assets. The small-molecule and RNA therapeutics biotech will also expand into CRISPR and gene therapy delivery in the coming year. read more By Emmy Lucas Apple Tree Partners has picked its first U.K.-based venture to launch: Adendra Therapeutics, an immunotherapy company focused on dendritic cell biology to treat cancers and autoimmune diseases. Adendra eked out $53 million in a series A financing to help with its launch. read more By Arlene Weintraub Using stem cell models derived from Alzheimer's patients, researchers at the Cleveland Clinic discovered that the erectile dysfunction drug Viagra (sildenafil) targets tau, one of the proteins implicated in the disease. They're now planning a phase 2 trial of Viagra in Alzheimer’s patients. read more By Fraiser Kansteiner Singapore has attracted a slate of pharma heavyweights in recent years. Now, a Merck and Welcome Trust joint venture is throwing its hat in the ring. read more By Rebecca Torrence Many physicians still aren't sold on the use of consumer wearables in healthcare, identifying key concerns around data accuracy and integration with EHRs, according to a Deloitte Global report. read more By Conor Hale An initial analysis by the FDA of commonly used COVID-19 tests found that while the omicron variant may produce an identifiable pattern in their results, that pattern alone is not enough to make a definitive omicron diagnosis. The agency recommended healthcare providers prioritize the full sequencing of those positive samples. read more Resources Sponsored by: WIRB - Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored By: BBK Worldwide Create more inclusive clinical trials, enroll them faster, and keep participants engaged longer with the latest Study Voices survey results and insights. Sponsored by: GLG A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more. Sponsored by: GLG Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Clario This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce Virtual Clinical Trials Summit December 6-7, 2021 | Philadelphia, PA Fierce JPM Week 2022 January 11, 2022 | San Francisco, CA
January 18-20, 2022 | Virtual Event Fierce Drug Safety Summit February 8-9, 2022 | Arlington, VA Fierce Business Development and Licensing Summit March 2022 | San Francisco, CA Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Health IT Summit April 20, 2022 | Virtual Event Fierce Trial Master File Summit May 2022 | Location TBD Fierce Digital Pharma Innovation Week June 2022 | Virtual Event Fierce Biotech Next-Gen June 29, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce Biotech Forum October 2022 | Location TBD Fierce Biotech Virtual Forum October 19, 2022 | Virtual Event | 